Bionomics Reports P-II Study (PREVAIL) Results of BNC210 for the Treatment of Social Anxiety Disorder
Shots:
- The P-II study (PREVAIL) evaluating the safety, tolerability, and efficacy of BNC210 (225/675mg) vs PBO in a ratio (1:1:1) in 151 adult patients with SAD across 15 sites in the US
- The trial failed to meet its 1EPs as measured by the change from baseline to the avg. of SUDS scores during a 5min. public speaking challenge while the patients with confirmed SAD who received BNC210 exhibited trends toward improvements across EPs over PBO. The therapy also showed a favorable safety and tolerability profile that was consistent with prior results
- The therapy is currently being studied in an ongoing P-IIb study (ATTUNE) for the treatment of PTSD with expected results in mid-2023
Ref: Bionomics | Image: Bionomics
Related news:- Bionomics Reports P-II Study (PREVAIL) Results of BNC210 for the Treatment of Social Anxiety Disorder
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
